Woodcock testifies on generic labeling proposal before House panel

04/2/2014 | Reuters

The makers of generic drugs should have to issue health warnings for all known risks of the medications they sell, just as the makers of branded medications do, the FDA's Dr. Janet Woodcock told a U.S. House of Representatives health subcommittee. "The goal is to make sure the whole system is searching for safety problems and updating labels when they are found," said Woodcock, director of the agency's Center for Drug Evaluation and Research.

View Full Article in:


Published in Brief: